Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists deliberately infect volunteers with dengue to unlock immune secrets

NCT ID NCT07706686

Recruiting now Knowledge-focused Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 24, 2026 · Updated 6 times

Summary

This study aims to understand how the human body responds to dengue virus infection, including in people who have had dengue before. Healthy volunteers aged 18 to 50 receive a single injection of a weakened dengue virus and are closely monitored for six months. Researchers measure viral levels, immune responses, and any symptoms to compare how first-time and repeat infections differ.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a live attenuated dengue virus called rDEN2delta30-7169
What this could lead to
If successful, this study could reveal how the immune system fights dengue, pointing toward better treatments or vaccines.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply broadly. The virus is weakened but may still cause mild symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DENGUE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dengue disease viral infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DENGUE HEALTHY VOLUNTEERS HUMAN CHALLENGE TRIAL

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.